Gilder Gagnon Howe & Co’s DexCom DXCM Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-439,386	Closed	-$49.8M	–	255
2024 Q2	$49.8M	Sell	439,386 -32,113	-7%	-$4.06M	0.62%	49
2024 Q1	$65.4M	Sell	471,499 -10,682	-2%	-$1.34M	0.82%	36
2023 Q4	$59.8M	Sell	482,181 -19,320	-4%	-$1.97M	0.82%	36
2023 Q3	$46.8M	Sell	501,501 -65,830	-12%	-$7.42M	0.71%	45
2023 Q2	$72.9M	Sell	567,331 -38,633	-6%	-$4.67M	1%	29
2023 Q1	$70.4M	Sell	605,964 -31,106	-5%	-$3.48M	1.17%	26
2022 Q4	$72.1M	Sell	637,070 -1,715	-0.3%	-$188K	1.35%	20
2022 Q3	$51.4M	Sell	638,785 -72,117	-10%	-$6.11M	0.9%	31
2022 Q2	$53M	Sell	710,902 -117,490	-14%	-$10.7M	0.94%	30
2022 Q1	$106M	Sell	828,392 -5,716	-0.7%	-$625K	0.98%	27
2021 Q4	$112M	Sell	834,108 -17,396	-2%	-$2.5M	0.64%	50
2021 Q3	$116M	Sell	851,504 -11,740	-1%	-$1.48M	0.6%	53
2021 Q2	$92.2M	Sell	863,244 -81,844	-9%	-$7.86M	0.45%	65
2021 Q1	$84.9M	Sell	945,088 -78,104	-8%	-$7.33M	0.46%	67
2020 Q4	$94.6M	Sell	1,023,192 -783,832	-43%	-$70M	0.47%	65
2020 Q3	$186M	Sell	1,807,024 -208,448	-10%	-$21.8M	1.15%	20
2020 Q2	$204M	Sell	2,015,472 -339,712	-14%	-$30.4M	1.6%	13
2020 Q1	$159M	Sell	2,355,184 -229,068	-9%	-$14.3M	1.9%	11
2019 Q4	$141M	Sell	2,584,252 -76,980	-3%	-$3.65M	1.47%	13
2019 Q3	$99.3M	Sell	2,661,232 -363,868	-12%	-$14.1M	1.14%	24
2019 Q2	$113M	Buy	3,025,100 +306,040	+11%	+$9.62M	1.14%	21
2019 Q1	$81M	Sell	2,719,060 -231,036	-8%	-$8.12M	0.86%	43
2018 Q4	$88.4M	Buy	2,950,096 +148,148	+5%	+$4.7M	1.25%	24
2018 Q3	$100M	Buy	2,801,948 +415,028	+17%	+$12.9M	1.02%	30
2018 Q2	$56.7M	Buy	2,386,920 +39,676	+2%	+$841K	0.61%	53
2018 Q1	$43.5M	Buy	2,347,244 +1,811,988	+339%	+$26.8M	0.54%	59
2017 Q4	$7.68M	Buy	+535,256	New	+$6.96M	0.1%	138
2017 Q3	–	Sell	-173,692	Closed	-$3.18M	–	289
2017 Q2	$3.18M	Sell	173,692 -1,638,128	-90%	-$30.3M	0.05%	168
2017 Q1	$38.4M	Sell	1,811,820 -287,156	-14%	-$5.6M	0.65%	49
2016 Q4	$31.3M	Sell	2,098,976 -695,592	-25%	-$12.3M	0.62%	51
2016 Q3	$61.2M	Sell	2,794,568 -349,620	-11%	-$7.78M	1.05%	29
2016 Q2	$62.4M	Sell	3,144,188 -84,292	-3%	-$1.44M	1.24%	25
2016 Q1	$54.8M	Sell	3,228,480 -322,408	-9%	-$5.39M	1.08%	25
2015 Q4	$72.7M	Sell	3,550,888 -19,800	-0.6%	-$412K	1.17%	20
2015 Q3	$76.6M	Sell	3,570,688 -300,992	-8%	-$6.72M	1.22%	21
2015 Q2	$77.4M	Sell	3,871,680 -1,013,736	-21%	-$17.8M	1.02%	28
2015 Q1	$76.1M	Sell	4,885,416 -2,629,964	-35%	-$39.7M	1.06%	29
2014 Q4	$103M	Sell	7,515,380 -8,167,996	-52%	-$100M	1.54%	19
2014 Q3	$157M	Sell	15,683,376 -76,620	-0.5%	-$783K	2.28%	9
2014 Q2	$156M	Sell	15,759,996 -125,792	-0.8%	-$1.11M	2.07%	9
2014 Q1	$164M	Sell	15,885,788 -275,660	-2%	-$2.85M	2.24%	7
2013 Q4	$143M	Sell	16,161,448 -135,280	-0.8%	-$1.07M	2.04%	8
2013 Q3	$115M	Buy	16,296,728 +1,319,452	+9%	+$8.36M	1.8%	13
2013 Q2	$84.1M	Buy	+14,977,276	New	+$71.7M	1.59%	14

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Gilder Gagnon Howe & Co's DXCM Position: Q3 2024 in Review

Gilder Gagnon Howe & Co sold out of DexCom (DXCM) in Q3 2024, closing a stake of 439,386 shares — an estimated $49.8M sold.

Gilder Gagnon Howe & Co first reported a position in DXCM in Q2 2013 and held it in 44 quarters. The position peaked at $204M in Q2 2020. 890 funds tracked by Wall St. Rank hold DXCM as of Q3 2024.

Gilder Gagnon Howe & Co reported no remaining DexCom position as of Q3 2024 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 439,386 DexCom shares in Q3 2024, an estimated $49.8M.
Gilder Gagnon Howe & Co first reported a position in DexCom in Q2 2013 and held it in 44 quarters.
Gilder Gagnon Howe & Co's DexCom position peaked at $204M in Q2 2020.
890 funds tracked by Wall St. Rank held DexCom as of Q3 2024.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2024, filed 14 Nov 2024.